bluuebunny/crossref_metadata_2025_split huggingface dataset:
A die rotating system for moderations of extrusion load and pressure drop profiles for molten PP and wood/polypropylene composites in extrusion processes
Authors: Intawong Naret , Kantala Chatchawan , Lotaisong Watit , Sombatsompop Narongrit 
Published: November 2010

AbstractA die‐rotating system was proposed in this work for moderations of extrusion forces and entrance pressure drop for molten polypropylene (PP) and wood/polypropylene (WPP) composites in a capillary rheometer and a single screw extruder. The effects of processing conditions and wood loading in PP were of our interests. The extrusion force and entrance pressure drop with and without the die rotating system were monitored in real‐time. This was the first time that the die‐rotating system was used for processing of highly viscous wood/polymer composite materials. It was found that the flow properties of the molten PP and WPP composites obeyed pseudoplastic non‐Newtonian behavior. The behavior was more obvious at wood contents of above 6 wt % and in the capillary rheometer. The rotation of the die could moderate the extrusion load by 60% and entrance pressure drop by 20% in the capillary rheometer, and the entrance pressure drop by 30% in the single screw extruder, especially at the conditions where the viscosities of the WPP and the extrusion rate were high. Greater fluctuations in entrance pressure drop caused by die rotation were observed in the single screw extruder. © 2010 Wiley Periodicals, Inc. J Appl Polym Sci 120:1006–1016, 2011
Multiscale motion saliency for keyframe extraction from motion capture sequences
Authors: Halit Cihan , Capin Tolga 
Published: November 2010

AbstractMotion capture is an increasingly popular animation technique; however data acquired by motion capture can become substantial. This makes it difficult to use motion capture data in a number of applications, such as motion editing, motion understanding, automatic motion summarization, motion thumbnail generation, or motion database search and retrieval. To overcome this limitation, we propose an automatic approach to extract keyframes from a motion capture sequence. We treat the input sequence as motion curves, and obtain the most salient parts of these curves using a new proposed metric, called 'motion saliency'. We select the curves to be analysed by a dimension reduction technique, Principal Component Analysis (PCA). We then apply frame reduction techniques to extract the most important frames as keyframes of the motion. With this approach, around 8% of the frames are selected to be keyframes for motion capture sequences. Copyright © 2010 John Wiley & Sons, Ltd.
Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation
Authors: Nuis Rutger‐Jan M. , Van Mieghem Nicolas M. , Tzikas Apostolos , Piazza Nicolo , Otten Amber M. , Cheng Jin , van Domburg Ron T. , Betjes Michiel , Serruys Patrick W. , de Jaegere Peter P.T. 
Published: November 2010

AbstractObjectives: To determine the frequency and independent predictors of acute kidney injury (AKI) in addition to the prognostic implications of both AKI and periprocedural red blood cell (RBC) transfusions on 30 day and cumulative late mortality in patients undergoing transcatheter aortic valve implantation (TAVI). Background: RBC transfusions have been reported to predict AKI following TAVI. Data on the prognostic implications of both factors, however, are lacking. Methods: 126 consecutive patients underwent TAVI with the Medtronic CoreValve Revalving System. AKI was defined according to the valve academic research consortium definitions as an absolute increase in serum creatinine ≥0.3 mg dL−1 (≥26.4 μmol L−1) or a percentage increase ≥50% within 72 hr following TAVI. Results: Five patients on chronic haemodialysis and three intraprocedural deaths were excluded, leading to a final study population of 118 patients. AKI occurred in 19% of the patients necessitating temporary haemodialysis in 2%. Independent predictors of AKI included: previous myocardial infarction (OR: 5.72; 95% CI: 1.64–19.94), periprocedural (<24 hr) RBC transfusions (OR: 1.29; 95% CI: 1.01–1.70), postprocedural (<72 hr) leucocyte count (OR: 1.18; 95% CI: 1.02–1.37), and logistic EuroSCORE (OR: 1.08; 95% CI: 1.01–1.14). In patients with AKI, 30‐day mortality was 23% and cumulative late mortality (median: 13 months) was 55%. AKI (OR: 5.47; 95% CI: 1.23–24.21) and postprocedural leucocyte count (OR: 1.20; 95% CI: 1.03–1.38) were independent predictors of 30‐day mortality while AKI (HR: 2.79; 95% CI: 1.36–5.71) was the only independent predictor of late mortality. Conclusions: AKI following TAVI occurred in 19% of the patients. RBC transfusion was found to be an independent predictor of AKI, which in turn predicted both 30‐day and cumulative late mortality. © 2011 Wiley‐Liss, Inc.
Detection and clinical outcome of urinary bladder cancer with 5‐aminolevulinic acid‐induced fluorescence cystoscopy
Authors: Stenzl Arnulf , Penkoff Hannes , Dajc‐Sommerer Elfriede , Zumbraegel Andreas , Hoeltl Lorenz , Scholz Michael , Riedl Claus , Bugelnig Josef , Hobisch Alfred , Burger Maximilian , Mikuz Gregor , Pichlmeier Uwe 
Published: November 2010

AbstractBACKGROUND:The medical community lacks results from prospective controlled multicenter studies of the diagnostic efficacy of 5‐aminolevulinic acid (5‐ALA) cystoscopy on tumor recurrence in patients with superficial bladder tumors.METHODS:A prospective randomized, double‐blind, placebo‐controlled study was conducted in 370 patients with nonmuscle‐invasive urinary bladder carcinoma who received either 5‐ALA (n = 187) or a placebo (n = 183) intravesically before cystoscopy. Each group underwent cystoscopy under visible white light and under fluorescent light followed by transurethral tumor resection. The primary study objective was to evaluate the 12‐month recurrence‐free survival.RESULTS:Slightly more patients with tumors were detected by using 5‐ALA than by using the placebo (88.5% vs 84.7%). The mean numbers of tumor specimens per patient were 1.8 (5‐ALA) and 1.6 (placebo). Intrapatient comparison of fluorescent light versus white light cystoscopy in patients randomized to receive 5‐ALA showed a higher tumor detection rate with fluorescent light than with white light cystoscopy. In patients receiving 5‐ALA cystoscopy, the percentage of lesions that would not have been detected in these patients by white light cystoscopy ranged between 10.9% (pT1) and 55.9% (atypia). Progression‐free survival was 89.4% (5‐ALA) and 89.0% (placebo) (P = .9101), and recurrence‐free survival 12 months after tumor resection was 64.0% (5‐ALA) and 72.8% (placebo) (P = .2216).CONCLUSIONS:In comparison to the placebo, 5‐ALA cystoscopy did not increase the rates of recurrence‐free or progression‐free survival 12 months after tumor resection. Although more tumors per patient were detected in the 5‐ALA group, the higher detection rate did not translate into differences in long‐term outcome. Cancer 2011. © 2010 American Cancer Society.
The use of recombinant erythropoietin for the treatment of chemotherapy‐induced anemia in patients with ovarian cancer does not affect progression‐free or overall survival
Authors: Cantrell Leigh A. , Westin Shannon N. , Van Le Linda 
Published: November 2010

AbstractBACKGROUND.Studies have suggested that erythropoietin‐stimulating agents (ESAs) may affect progression‐free survival (PFS) and overall survival (OS) in a variety of cancer types. Because this finding had not been explored previously in ovarian or primary peritoneal carcinoma, the authors of this report analyzed their ovarian cancer population to determine whether ESA treatment for chemotherapy‐induced anemia affected PFS or OS.METHODS.A retrospective review was conducted of women who were treated for ovarian cancer at the corresponding author's institution over a 10‐year period (from January 1994 to May 2004). Treatment groups were formed based on the use of an ESA. Two analyses of survival were conducted to determine the effect of ESA therapy on PFS and OS. Disease status was modeled as a function of treatment group using a logistic regression model. Kaplan‐Meier curves were generated to compare the groups, and a Cox proportional hazards model was fit to the data.RESULTS.In total, 343 women were identified. The median age was 57 (interquartile range, 48‐68 years). The majority of women were Caucasian (n = 255; 74%) and were diagnosed with stage III (n = 210; 61%), epithelial (n = 268; 78%) ovarian cancer. Although the disease stage at diagnosis and surgical staging significantly affected the rates of disease recurrence and OS, the receipt of an ESA had no effect on PFS (P = .9) or OS (P = .25).CONCLUSIONS.The current results indicated that there was no difference in cancer‐related PFS or OS with use of ESA in this cohort of women treated for ovarian cancer. Cancer 2011. © 2010 American Cancer Society.
Efficacy and safety of clofarabine in relapsed and/or refractory non‐hodgkin lymphoma, including rituximab‐refractory patients
Authors: Nabhan Chadi , Davis Nancy , Bitran Jacob D. , Galvez Angel , Fried Walter , Tolzien Kathy , Foss Susan , Dewey Wendy M. , Venugopal Parameswaran 
Published: November 2010

AbstractBACKGROUND:Currently, no standard therapy exists for patients with relapsed and/or refractory non‐Hodgkin lymphoma (NHL) who are ineligible for transplantation or who have failed after bone marrow transplantation. The authors of this report investigated the safety and efficacy of clofarabine (CLO) in these patients.METHODS:In a 2‐step, open‐label study, CLO (as a 1‐hour intravenous infusion given daily for 5 days) was given every 28 days (maximum, 6 cycles). In the phase 1 portion (n = 7; standard 3 + 3 study design), the dose was escalated by 2 mg/m2 to determine the maximum tolerated dose (MTD). The phase 2 study (n = 26) was initiated at the MTD, and patients were followed until disease progression.RESULTS:Of 33 patients who were enrolled, 31 patients (median age, 69 years) were evaluable; 24% failed after previous stem cell transplantation, and 72% were rituximab‐refractory. The MTD for CLO was 4 mg/m2. The overall response rate was 42%. Seven patients (23%) achieved a complete response, and 6 patients (19%) achieved a partial response. The median response duration was 5 months. Among the rituximab‐refractory patients, the overall response rate was 47% (complete response rate, 28%), and the median response duration was 7 months. At a median follow‐up of 14 months, 45% of patients remained alive (median overall survival, 10 months). Toxicity was mainly hematologic (≥60% of patients had neutropenia or thrombocytopenia). Nonhematologic toxicity included tumor lysis syndrome, infection, and renal insufficiency (in 6% of patients each). No treatment‐related mortality was observed.CONCLUSIONS:Single‐agent CLO was active and was tolerated well in patients with refractory NHL, including patients in a rituximab‐refractory subset. Reversible myelosuppression was the major toxicity. Study is registered at www.clinicaltrials.gov (NCT00156013). Cancer 2011. © 2010 American Cancer Society.
Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers
Authors: Baba Yoshifumi , Nosho Katsuhiko , Shima Kaori , Hayashi Marika , Meyerhardt Jeffrey A. , Chan Andrew T. , Giovannucci Edward , Fuchs Charles S. , Ogino Shuji 
Published: November 2010

AbstractBACKGROUND:AKT (AKT1, AKT2, and AKT3) was a downstream effector of phosphatidylinositide‐3‐kinase (PI3K) and played crucial roles in protein synthesis, cellular metabolism, survival, and proliferation. The PI3K/AKT pathway was commonly activated in human cancers and was recognized as a potential target for anticancer therapy. Nonetheless, clinical, molecular, or prognostic features of AKT‐activated colon cancer remained uncertain.METHODS:Using a database of 717 colon and rectal cancers in the Nurses' Health Study and the Health Professionals Follow‐up Study, Ser473 phosphorylated AKT (p‐AKT) expression was detected in 448 (62%) tumors by immunohistochemistry. Cox proportional hazards model was used to compute mortality hazards ratio (HR), adjusting for clinical and tumoral features, including PIK3CA, KRAS, BRAF, microsatellite instability (MSI), CpG island methylator phenotype (CIMP), LINE‐1 methylation, TP53 (p53), and FASN (fatty acid synthase).RESULTS:Tumor p‐AKT expression was associated with PIK3CA mutation (odds ratio [OR], 1.77; 95% confidence interval [CI], 1.12‐2.80; P = .015). p‐AKT expression was significantly associated with longer colorectal cancer‐specific survival in Kaplan‐Meier analysis (log‐rank P = .0005), univariate Cox regression (HR, 0.62; 95% CI, 0.47‐0.82; P = .0006) and multivariate analysis (adjusted HR, 0.75; 95% CI, 0.56‐0.99; P = .048) adjusting for clinical and molecular variables including PIK3CA, MSI, CIMP and LINE‐1 hypomethylation. p‐AKT expression was inversely associated with high stage (III‐IV) (adjusted OR, 0.63; 95% CI, 0.45‐0.88, P = .0071).CONCLUSIONS:p‐AKT expression in colorectal cancer is associated with low stage and good prognosis. p‐AKT may serve as a tissue biomarker to identify patients with superior prognosis and a possible therapeutic target (analogous to estrogen receptor ESR1 in breast cancer). Cancer 2011. © 2010 American Cancer Society.
Catechol‐O‐methyltransferase genotype modulates cancer treatment‐related cognitive deficits in breast cancer survivors
Authors: Small Brent J. , Rawson Kerri Sharp , Walsh Erin , Jim Heather S. L. , Hughes Tiffany F. , Iser Lindsay , Andrykowski Michael A. , Jacobsen Paul B. 
Published: November 2010

AbstractBACKGROUND:Recent attention has focused on the negative effects of chemotherapy on the cognitive performance of cancer survivors. The current study examined modification of this risk by catechol‐O‐methyltransferase (COMT) genotype based on evidence in adult populations that the presence of a Val allele is associated with poorer cognitive performance.METHODS:Breast cancer survivors treated with radiotherapy (n = 58), and/or chemotherapy (n = 72), and 204 healthy controls (HCs) completed tests of cognitive performance and provided saliva for COMT genotyping. COMT genotype was divided into Val carriers (Val+; Val/Val, Val/Met) or COMT‐Met homozygote carriers (Met; Met/Met).RESULTS:COMT‐Val+ carriers performed more poorly on tests of attention, verbal fluency, and motor speed relative to COMT‐Met homozygotes. Moreover, COMT‐Val+ carriers treated with chemotherapy performed more poorly on tests of attention relative to HC group members who were also Val+ carriers.CONCLUSIONS:The results suggest that persons treated with chemotherapy for breast cancer who also possess the COMT‐Val gene are susceptible to negative effects on their cognitive health. This research is important because it strives to understand the factors that predispose some cancer survivors to more negative quality‐of‐life outcomes. Cancer 2011. © 2010 American Cancer Society.
Periosteal osteosarcoma
Authors: Cesari Marilena , Alberghini Marco , Vanel Daniel , Palmerini Emanuela , Staals Eric L. , Longhi Alessandra , Abate Massimo , Ferrari Cristina , Balladelli Alba , Ferrari Stefano 
Published: November 2010

AbstractBACKGROUND:Periosteal osteosarcoma is a rare variant of osteosarcoma. Wide surgical removal is the mainstay of treatment, but controversy remains about the role of chemotherapy. The objective of this study was to review and analyze the clinical and treatment‐related factors that influence the survival of patients with periosteal osteosarcoma who received treatment in a single institution.METHODS:Thirty‐three patients with periosteal osteosarcoma (19 males and 14 females) with a median age of 16 years (range, ages 6‐32 years) underwent surgery (32 patients) and received radiotherapy (1 patient). Chemotherapy was received according to different regimens for high‐grade osteosarcoma by 14 patients who had grade 3 tumors.RESULTS:The 10‐year overall survival rate was 84%. The only patient who did not undergo surgery died of disease after 9 months; for the remaining 32 patients the 10‐year disease‐free survival rate was 65%. Survival was not influenced by the receipt of chemotherapy. The patients who received chemotherapy had a 10‐year overall survival rate of 86%, and those who received only local treatment had an overall survival rate of 83% (P = .73).CONCLUSIONS:The authors' experience indicated that the treatment of periosteal osteosarcoma requires only wide surgical removal of the tumor and that adjuvant chemotherapy does not improve survival. Cancer 2011. © 2010 American Cancer Society.
The implications of the 2010 patient protection and affordable care act and the health care and education reconciliation act on cancer care delivery
Authors: Albright Heidi W. , Moreno Mark , Feeley Thomas W. , Walters Ronald , Samuels Marc , Pereira Alissa , Burke Thomas W. 
Published: November 2010

AbstractIn March 2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. This legislation attempts to address cost control and improve the quality of healthcare in the United States. Cancer is a major health problem in the United States and the leading cause of death for Americans under the age of 80. Therefore, cancer care providers need to be fully engaged in ongoing discussions regarding quality measurement and care delivery. With the optimum level of collaboration and support, the proposals in the legislation can be properly structured to deliver improved access to care via better delivery systems, as well as more appropriate reimbursement to advance the prevention and treatment of cancer. Cancer 2011. © 2010 American Cancer Society.
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma
Authors: Meyers Paul A. , Healey John H. , Chou Alexander J. , Wexler Leonard H. , Merola Pamela R. , Morris Carol D. , Laquaglia Michael P. , Kellick Michael G. , Abramson Sara J. , Gorlick Richard 
Published: November 2010

AbstractBACKGROUND:This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma.METHODS:The authors treated 40 patients with osteosarcoma with cisplatin, doxorubicin, and methotrexate with the addition of pamidronate 2 mg/kg/dose (max dose 90 mg) monthly for 12 doses. Survival, event‐free survival (EFS), and durability of orthopedic reconstruction were evaluated.RESULTS:For patients with localized disease, event‐free survival (EFS) at 5 years was 72% and overall survival 93%. For patients with metastatic disease, EFS at 5 years was 45% and overall survival 64%. Toxicity was similar to patients treated with chemotherapy alone. Thirteen of 14 uncemented implants demonstrated successful osteointegration. Among allograft reconstructions, there were 2 graft failures, 4 delayed unions, and 6 successful grafts. Overall, 5 of 33 reconstructions failed. There were no stress fractures or growth disturbances.CONCLUSIONS:Pamidronate can be safely incorporated with chemotherapy for the treatment of osteosarcoma. It does not impair the efficacy of chemotherapy. Pamidronate may improve the durability of limb reconstruction. Cancer 2011. © 2010 American Cancer Society.
The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy
Authors: Hayashi Yuki , Correa Arlene M. , Hofstetter Wayne L. , Vaporciyan Ara A. , Rice David C. , Walsh Garrett L. , Mehran Reza J. , Lee Jeffrey H. , Bhutani Manoop S. , Dekovich Alexander , Swisher Stephen G. , Ajani Jaffer A. 
Published: November 2010

AbstractBACKGROUND:High body mass index (BMI), a prevalent condition in the United States, is associated with esophageal adenocarcinoma (EAC). Its influence on a patient's outcome remains unclear. In the current study, the authors examined the impact of BMI on survival and complications in patients with esophageal cancer (EC) who underwent surgery as their primary therapy.METHODS:The authors retrospectively reviewed 301 consecutive EC patients who underwent surgery but received no adjunctive therapy. Patients were segregated into 2 subgroups based on their baseline BMI: normal/low (<25 kg/m2) and high (≥25 kg/m2).RESULTS:Seventy‐six (25%) patients had a BMI <25 kg/m2 and 225 (75%) patients had a BMI ≥25 kg/m2. In the high BMI group, there were more men (P < .001), fewer upper ECs (P = .021), a lower baseline clinical stage (P = .006), and frequent EAC (P < .001). Postoperative morbidity was similar in both groups, with the exception of gastrointestinal complications (P = .016). The 5‐year overall survival (OS) rates were 44% in the normal/low BMI group and 60% in the high BMI group (P = .017). The 5‐year disease‐free survival (DFS) rates were 41% in the normal/low BMI group and 60% in the high BMI group (P = .005). On multivariable analysis, age, weight loss, peripheral vascular disease (PVD), and both clinical and pathological stage of disease were found to be independent prognosticators for OS. Older age (hazard ratio [HR], 1.029; 95% confidence interval [95% CI], 1.009‐1.049 [P = .004]), weight loss (HR, 1.525; 95% CI, 1.034‐2.248 [P = .033]), and PVD (HR, 2.325; 95% CI, 1.039‐5.204 [P = .040]) were found to be associated with poor OS.CONCLUSIONS:High BMI is common in EC patients and the better OS/DFS noted in patients with a high BMI is because of the diagnosis of a low baseline clinical stage. Confirmation of these findings is warranted. Cancer 2010. © 2010 American Cancer Society.
Cardiopulmonary resuscitation training of family members before hospital discharge using video self‐instruction: A feasibility trial
Authors: Blewer Audrey L. , Leary Marion , Decker Christopher S. , Andersen James C. , Fredericks Amanda C. , Bobrow Bentley J. , Abella Benjamin S. 
Published: November 2010

AbstractBACKGROUND:Bystander cardiopulmonary resuscitation (CPR) is a crucial therapy for sudden cardiac arrest (SCA), yet rates of bystander CPR are low. This is especially the case for SCA occurring in the home setting, as family members of at‐risk patients are often not CPR trained.OBJECTIVE:To evaluate the feasibility of a novel hospital‐based CPR education program targeted to family members of patients at increased risk for SCA.DESIGN:Prospective, multicenter, cohort study.SETTING:Inpatient wards at 3 hospitals.SUBJECTS:Family members of inpatients admitted with cardiac‐related diagnoses.MEASUREMENTS AND RESULTS:Family members were offered CPR training via a proctored video‐self instruction (VSI) program. After training, CPR skills and participant perspectives regarding their training experience were assessed. Surveys were conducted one month postdischarge to measure the rate of “secondary training” of other individuals by enrolled family members. At the 3 study sites, 756 subjects were offered CPR instruction; 280 agreed to training and 136 underwent instruction using the VSI program. Of these, 78 of 136 (57%) had no previous CPR training. After training, chest compression performance was generally adequate (mean compression rate 90 ± 26/minute, mean depth 37 ± 12 mm). At 1 month, 57 of 122 (47%) of subjects performed secondary training for friends or family members, with a calculated mean of 2.1 persons trained per kit distributed.CONCLUSIONS:The hospital setting offers a unique “point of capture” to provide CPR instruction to an important, undertrained population in contact with at‐risk individuals. Journal of Hospital Medicine 2011. © 2010 Society of Hospital Medicine.